New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 11, 2014
11:31 EDTINO, SD, CREE, GNC, OREX, WTW, INVN, UBNT, AEGR, SANOptions with increasing implied volatility
Options with increasing implied volatility: INO AEGR UBNT INVN WTW OREX GNC CREE SD SAN
News For INO;AEGR;UBNT;INVN;WTW;OREX;GNC;CREE;SD;SAN From The Last 14 Days
Check below for free stories on INO;AEGR;UBNT;INVN;WTW;OREX;GNC;CREE;SD;SAN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 11, 2014
07:06 EDTOREXOrexigen's Contrave weight management tablets approved by FDA
Orexigen Therapeutics and Takeda Pharmaceuticals U.S.A. jointly announced that the FDA has approved Contrave extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index indicating obese or overweight, in the presence of at least one weight-related comorbid condition. Takeda is planning to commercially launch Contrave in the fall.
06:49 EDTOREXFDA approves weight management drug Contrave
The U.S. Food and Drug Administration yesterday approved Contrave as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. The drug is approved for use in adults with a body mass index of 30 or greater or adults with a BMI of 27 or greater who have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Contrave is a combination of two FDA-approved drugs, naltrexone and bupropion, in an extended-release formulation. The effectiveness of Contrave was evaluated in multiple clinical trials that included approximately 4,500 obese and overweight patients with and without significant weight-related conditions treated for one year. Contrave is distributed by Takeda Pharmaceuticals America (TKPYY) for Orexigen Therapeutics (OREX).
September 10, 2014
18:27 EDTOREXOrexigen trading halted, pending news
Subscribe for More Information
11:48 EDTSANBanco Santander confirms appointment of Ana Botin as board chair
Subscribe for More Information
10:21 EDTSANBotin daughter likely to succeed father as chairwoman, Reuters says
Subscribe for More Information
06:03 EDTSANBanco Santander chairman Botin passes away
Banco Santander regrets to announce that its chairman, Emilio Botin, has passed away. In accordance with the procedures set out in article 24 of the board rules, the appointments and remuneration committee and the board of directors will meet today to appoint a new chairman of the bank. Reference Link
September 9, 2014
15:27 EDTOREXOrexigen volatility elevated
Subscribe for More Information
13:37 EDTINVNInvenSense rises 2.5% during Apple iPhone launch event
InvenSense (INVN) provides intelligent motion processing solutions. Apple (AAPL) discussed the motion sensing capabilities of its new phone during the launch presentation.
12:46 EDTOREXNovo Nordisk weight loss drug helped people get thinner, Bloomberg reports
Subscribe for More Information
12:08 EDTINOOptions with increasing implied volatility
Subscribe for More Information
10:13 EDTCREECree calls active on takeover speculation
Subscribe for More Information
09:52 EDTCREERumor: Cree strength attributed to takeover speculation
September 8, 2014
17:22 EDTOREXOrexigen, Takeda Pharmaceutical in services agreement
Orexigen disclosed in a regulatory filing that in preparation for the potential launch of NB32, Orexigen Therapeutics (OREX) and Takeda Pharmaceutical Company (TKPYY) entered into a Manufacturing Services Agreement, dated September 2, in accordance with the Collaboration Agreement between the company and Takeda, effective as of September 1, 2010, as amended by Amendment Number 1 to Collaboration Agreement effective as of September 26, 2013. Pursuant to the Agreement, among other things, the company will supply to Takeda, and Takeda will, subject to certain exceptions as set forth in the Agreement and Collaboration Agreement, exclusively purchase from the Company, all of Takeda’s requirements of NB32 for commercialization in the United States, Canada and Mexico during the term of the Collaboration Agreement. The Agreement will continue in full force and effect until the expiration or termination of the Collaboration Agreement.
08:09 EDTUBNTUbiquiti Networks initiated with an Outperform at FBN Securities
Target $55.
September 5, 2014
09:17 EDTINVNInvenSense recent price action creates attractive entry point, says RW Baird
Subscribe for More Information
07:18 EDTSANRegulators drafting flexible 'bail in' bond deal for large banks, Reuters says
Subscribe for More Information
September 4, 2014
18:28 EDTSDOn The Fly: After Hours Movers
Subscribe for More Information
16:22 EDTSDSandRidge Energy announces $200M share repurchase program
Subscribe for More Information
11:05 EDTSAN, INOOptions with increasing implied volatility
Subscribe for More Information
09:02 EDTINOInovio to list on NASDAQ
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use